Table 1 Basic characteristics of included studies
Author | Country | Year | Population | Age (Mean + SD) | Total/male/female | Intervention | Control | Outcome |
|---|---|---|---|---|---|---|---|---|
Bjørnholdt et al. [16] | Denmark | 2015 | Patients scheduled for primary shoulder replacement | LIA: 65 ± 8; cISB: 66 ± 8 | LIA: 30/15/15; cISB:31 9/22 | cISB | LIA | VAS/mc/AHS |
Okoroha et al. [22] | USA | 2016 | Patients undergoing shoulder arthroplasty | ssISB:67.1 ± 8.6; LB: 69.4 ± 8.9 | ssISB:31/16/15;LB:26/12/14 | ssISB | LB | VAS/mc/AHS |
Abildgaard et al. [23] | Denmark | 2017 | Patients undergoing shoulder arthroplasty | cISB:NA LB:NA | IINB: 46/14/32; LB: 37/21/16 | cISB | LB | VAS/mc/AHS |
Sabesan et al. [18] | USA | 2017 | Patients undergoing shoulder arthroplasty | CISB: 65 ± NA; LB: 63 ± NA | cISB:36/19/17; LB:34/25/9 | cISB | LB | VAS/mc/AHS |
Namdari et al. [24] | USA | 2017 | Patients scheduled for total shoulder arthroplasty | LB:70.9 ± 9.3 ssISB:68.4 ± 8.2 | LB:78/31/47; ssISB:78/40/38 | ssISB | LB | VAS/mc |
Namdari et al. [25] | USA | 2018 | Patients undergoing shoulder arthroplasty | ssISB:71.2 ± 8.6; cISB:68.6 ± 10.0 | ssISB:39/24/15;cISB:39/19/20 | cISB | ssISB | VAS/mc/AHS |
Panchamia et al. [17] | USA | 2019 | Patients receiving local infiltration analgesia or interscalene block after shoulder arthroplasty | LB: 69.5 ± 8.9; ssISB: 67.8 ± 13.1; cISB: 68.1 ± 10.1 | LIA:42/25/17;ssISB:42/20/22; cISB:41/19/22 | cISB | ssISB, LB | VAS/mc |
Sicard et al. [11] | France | 2019 | Patients undergoing shoulder arthroplasty | LIA: 72.2 ± 10.1; cISB: 71.7 ± 9 | LIA:50/14/36; cISB: 49/21/28 | cISB | LIA | VAS/mc/AHS |
Hattrup et al. [26] | USA | 2021 | Patients undergoing shoulder arthroplasty | LB:69.2 ± 10.15 ssISB:70.0 ± 6.84 | LB:52/28/24 ssISB:52/30/22 | ssISB | LB | VAS/mc |
Krupp et al. [10] | USA | 2023 | Patients undergoing shoulder arthroplasty | ssISB:66.9 ± NA cISB: 67.1 ± NA | ssISB:21/14/7; cISB:33/15/18 | cISB | ssISB | VAS/mc/AHS |
Levin et al. [27] | USA | 2022 | Patients undergoing primary total shoulder arthroplasty | LB:69 ± 10; cISB: 69 ± 9 | LB:323/140/183; cISB:242/105/137 | cISB | LB | VAS/mc |
Ewing et al. [28] | USA | 2022 | Patients undergoing primary total shoulder arthroplasty | LIA: 70.5 ± 9.7 cISB:68.9 ± 8.5 | LIA:37/28/9 cISB:37/24/13 | cISB | LIA | VAS/mc/AHS |